President Barack Obama has presented a Medal of Technology and Innovation to the IBM Blue Gene series of energy-efficient supercomputers, as used by the US Department of Energy's (DOE) Argonne and Lawrence Livermore national laboratories. Both sites contributed critical input and software components through a DOE research and development partnership with IBM that strongly impacted Blue Gene’s extreme-scale design.
' The success of this partnership is an excellent example of how national laboratories can help fuel industry and drive innovation,' said William Brinkman, Director of DOE's Office of Science. 'The Blue Gene supercomputers are an outstanding example of our investment in nuclear security providing the tools to tackle broader national challenges,' said National Nuclear Security Administration (NNSA) Administrator Thomas D'Agostino. 'This machine, which was originally developed to ensure the safety and reliability of our nuclear stockpile without testing, has led to amazing advances in science and discovery. I congratulate IBM, Lawrence Livermore National Laboratory and Argonne National Laboratory for a job well done.'DOE, which leads the world in providing supercomputers for scientific research, began an R&D partnership with IBM in 2001 to develop the Blue Gene platform. Argonne, together with Lawrence Livermore National Laboratory (LLNL), worked on key aspects of the design and provided critical software components to ensure it was well suited to solve challenges in energy, the environment and national security.
'The Blue Gene architecture has greatly enhanced the National Nuclear Security Administration's capability for predictive simulation and uncertainty quantification,' said Mark Seager, assistant deputy head for Advanced Computing Technology at LLNL.
Another critical aspect of the Blue Gene's success was ensuring the platform was adopted by the high-performance computing community. In 2004, Argonne and IBM jointly created the Blue Gene Consortium, an international group of laboratory, university and industrial researchers collaborating to evaluate the technology and platform and provide critical feedback for future Blue Gene designs.
'It is an honour and a privilege to be part of this partnership,' said Beckman. 'The Blue Gene/P is already making a measurable impact on the research community and enabling advancements that will shape our future.'